twenty-six patients ( 14 men and 12 women ) with histologically proven advanced malignant melanoma , who previously had not responded to dtic , methyl-ccnu , and procarbazine , received estramustine phosphate ( estracyt ) ( 15 mg/m2 ) in daily divided doses .
C0025202
malignant melanoma
C0010927
dtic